Trial Profile
Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of STOCRIN in Usual Practice.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Efavirenz (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 10 Jul 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov,
- 18 Oct 2011 Additional trial identifier added as reported by ClinicalTrials.gov
- 19 Feb 2010 New trial record